Document:

EXHIBIT 10.2

 

EXHIBIT
A

 

The
undersigned Daniel Wiesel, hereby certifies that:

 

1. He
is the Chairman of the Board of Directors and the Chief Executive Officer of The PAWS Pet Company, Inc., an Illinois corporation
(the “Corporation”).

 

2. The
Corporation is authorized to issue 10,000,000 shares of preferred stock, none of which are issued or outstanding.

 

3. That
on December 27, 2013 the following resolutions were duly adopted by the Board of Directors:

 

WHEREAS,
the Amended and Restated Articles of Incorporation, as amended to date, of the Corporation provide for a class of its authorized
stock known as preferred stock, comprised of 10,000,000 shares, no par value per share (the “Preferred Stock”), issuable
from time to time in one or more series;

 

WHEREAS,
the Board of Directors of the Corporation is authorized to fix the dividend rights, dividend rates, voting rights, conversion
rights, rights and terms of redemption and liquidation preferences of any wholly unissued series of Preferred Stock and the number
of shares constituting any series and designation thereof, of any of them;

 

NOW,
THEREFORE, BE IT RESOLVED, that the Board of Directors of the Corporation does hereby authorize this Certificate of Designation
of SERIES D CONVERTIBLE PREFERRED STOCK to provide for the issuance of a series of Preferred Stock for cash or exchange of other
securities, rights or property and does hereby fix and determine the rights, preferences, restrictions and other matters relating
to such series of Preferred Stock as follows:

 

TERMS
OF PREFERRED STOCK

 

ARTICLE
I. Designation, Amount and Par Value.

 

Section
1.01 The series of Preferred Stock shall be designated as the Corporation’s SERIES D CONVERTIBLE PREFERRED STOCK
(the “Series D Stock”) and the number of shares so designated shall be five hundred thousand (500,000), which
shall not be subject to increase without the affirmative vote or written consent of the holders (each a “Holder”
and collectively, the “Holders”) of at least sixty-seven percent (67%) of the Series D Stock issued and
outstanding at the time of any such vote or written consent. Each share of Series D Stock shall have no par value per
share.

 

ARTICLE
II. Ranking.

 

Section
2.01 The Series D Stock shall be, with respect to dividend rights and rights upon liquidation, winding-up or dissolution,
rank:

 

		(a)	Senior
                                         to the Corporation’s Common A Stock, no par value per share (“Common Stock”);
                                         and

 

		(b)	Equal
                                         to the Corporation’s Series B Convertible Preferred Stock, no par value per share
                                         (“Common Stock”); and

 

		(c)	Senior
                                         to any and all other classes or series of Preferred Stock of the Corporation, whether
                                         authorized now, or at any time in the future, unless any such subordination to any other
                                         class or series of Preferred Stock, is expressly agreed to, pursuant to an affirmative
                                         vote or written consent of Holders of at least sixty-seven percent (67%) of the Series
                                         D Stock issued and outstanding at the time of any such vote or written consent.

 

ARTICLE
III. Liquidation Rights.

 

Section
3.01 With respect to rights on Liquidation (as defined in Section 3.02 of this Article III), the Series D Stock shall
rank senior and prior to the any and all classes of the Corporation’s common stock and to any and all other classes or
series of preferred stock of the Corporation, except as otherwise approved by the affirmative vote or written consent
of the Holders of at least a sixty-seven percent (67%) of the Series D Stock issued and outstanding at the time of any such
vote or written consent. Furthermore, the Corporation may not designate any other class of common stock or preferred stock
without first obtaining the affirmative vote or consent of the Holders of at least sixty-seven percent (67%) of the Series D
Stock issued and outstanding at the time of any such vote or written consent.

 

    	Page 1 of 5

    	 

    

 

EXHIBIT
A

 

Section
3.02 In the event of any liquidation, dissolution or winding-up of the affairs of the Corporation (collectively, a
“Liquidation”), the sole participation to which the Holders of shares of Series D Stock then issued and
outstanding (the “Series D Stockholders”) shall be entitled, out of the assets of the Corporation legally
available for distribution to its stockholders, whether from capital, surplus or earnings, to receive, before any payment
shall be made to the holders of the Common Stock or any other class or series of preferred stock ranking on Liquidation
junior to such Series D Stock, an amount per share equal to the Face Value (as hereinafter defined). If upon any such
Liquidation, the remaining assets of the Corporation available for distribution to its shareholders shall be insufficient to
pay the Holders of shares of Series D Stock the full amount to which they shall be entitled, the Holders of shares of Series
D Stock, and of any class or series of stock ranking upon liquidation on a parity with the Series D Stock, shall share pari
passu in any distribution of the remaining assets and funds of the Corporation in proportion to the respective liquidation
amounts that would otherwise be payable to the Holders of preferred stock with respect to the shares held by them upon such
distribution if all amounts payable on or with respect to such shares were paid in full.

 

ARTICLE
IV. Restrictive Legend.

 

Section
4.01 Any Series D Stock certificate issued in reference to this designation shall bear on its face the following
restrictive legend:

 

THE
SHARES REPRESENTED BY THE CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND APPLICABLE STATE SECURITIES
LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED UNLESS, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER, THE
TRANSFER QUALIFIES FOR AN EXEMPTION FROM OR EXEMPTION TO THE REGISTRATION PROVISIONS THEREOF.

 

Section
4.02 For purposes of this CERTIFICATE OF DESIGNATION OF SERIES D CONVERTIBLE PREFERRED STOCK, the term “Valid
Exemption From or To Registration” shall mean, an exemption from or to registration, under the Securities Act of 1933
and applicable state securities laws and then, only after receipt, by the Corporation, its Transfer Agent and the Holder, of
an opinion of counsel which clearly states that such an exemption is available to the Holder.

 

ARTICLE
V. Conversion and Face Value.

 

Section
5.01 Any Holder of Series D Stock shall have the right to convert any or all of the Holder’s Series D Stock into a
number of fully paid and non-assessable shares of Common Stock for each share of Series D Stock so converted, as set forth in
this Article V.

 

		(a)	Any
                                         Series D Stockholder may exercise the right to convert such shares into Common Stock
                                         pursuant to this Article V by delivering to the Corporation during regular business hours,
                                         at the office of the Corporation or any transfer agent of the Corporation or at such
                                         other place as may be designated by the Corporation, the certificate or certificates
                                         for the shares to be converted (the “Series D Preferred Certificate”), duly
                                         endorsed or assigned in blank to the Corporation (if required by it).

 

		(b)	Each
                                         Series D Preferred Certificate shall be accompanied by written notice (the “Conversion
                                         Demand”) stating that such Holder elects to convert such shares and stating the
                                         name or names (with address) in which the certificate or certificates for the shares
                                         of Common Stock (the “Common Certificate”) are to be issued. Such conversion
                                         shall be deemed be effected on the date when such delivery is made, and such date is
                                         referred to herein as the “Conversion Date.”

 

    	Page 2 of 5

    	 

    

 

EXHIBIT
A

 

		(c)	As
                                         promptly as practicable thereafter, the Corporation shall issue and deliver to or upon
                                         the written order of such Holder, at the place designated by such Holder, a certificate
                                         or certificates for the number of shares of Common Stock calculated pursuant to this
                                         Article V, to which such Holder is entitled.

 

		(d)	The
                                         person in whose name the certificate or certificates for Common Stock are to be issued
                                         shall be deemed to have become a Holder of record of Common Stock on the applicable Conversion
                                         Date, unless the transfer books of the Corporation are closed on such Conversion Date,
                                         in which event the Holder shall be deemed to have become the stockholder of record on
                                         the next succeeding date on which the transfer books are open, provided that the Conversion
                                         Ratio (as hereinafter defined) shall be the Conversion Ratio in effect on the Conversion
                                         Date.

 

		(e)	Upon
                                         conversion of only a portion of the number of shares covered by a Series D Preferred
                                         Certificate, the Corporation shall issue and deliver to, or upon the written order of,
                                         the Holder of such Series D Preferred Certificate, at the expense of the Corporation,
                                         a new certificate covering the number of shares of the Series D Stock representing the
                                         unconverted portion of the Series D Preferred Certificate, which new certificate shall
                                         entitle the Holder thereof to all the rights, powers and privileges of a Holder of such
                                         shares.

 

		(f)	The
                                         number of shares to be issued in conversion of each share of Series D Stock upon receipt
                                         of a Conversion Demand shall be one thousand (1,000) Common shares for each Series D Stock
                                         share converted (the “Conversion Ratio”). The number of shares to be issued
                                         upon conversion may not be increased at any time without the consent of at least sixty-seven
                                         percent (67%) of all of the other series of preferred stock issued and outstanding at
                                         the time of any such vote or written consent.

 

Section
5.02 The Corporation shall pay all documentary, stamp or other transactional taxes (excluding income taxes) attributable
to the issuance or delivery of shares of capital stock of the Corporation upon conversion of any shares of Series D Stock;
provided, however, that the Corporation shall not be required to pay any taxes which may be payable in respect of any
transfer involved in the issuance or delivery of any certificate for such shares in a name other than that of the Holder of
the Series D Stock in respect of which such shares of Common Stock are being issued.

 

Section
5.03 The Corporation shall reserve out of its authorized, but unissued, shares of Common Stock, solely for the purpose of
effecting the conversion of the Series D Stock, sufficient shares of Common Stock to provide for the conversion of all
outstanding shares of Series D Stock.

 

Section
5.04 All shares of Common Stock which may be issued in connection with the conversion provisions set forth herein will,
upon issuance by the Corporation, be validly issued, fully paid and non-assessable, not subject to any preemptive or similar
rights and free from all taxes, liens or charges with respect thereto created or imposed by the Corporation.

 

Section
5.05 In no event, shall a Holder of any Series D Stock be allowed to convert such shares of Series D Stock into Common
Stock which, upon giving effect to such conversion, would cause the aggregate number of shares of Common Stock beneficially
owned by the Holder, and/or its affiliates, to exceed four and nine tenths percent (4.9%) of the currently issued and
outstanding shares of the Corporation. In reference to the written notice of election to convert required by Article V
Section 5.01 (b) above, the Holder shall affirm in that notice, under penalty of perjury, the exact number of shares held by
the Holder on the date of the notice and the Corporation shall have the right to reduce any demand for conversion by a number
such that the total number of shares of Common Stock held by the Holder after conversion will not exceed four and nine tenths
percent (4.9%) of the currently issued and outstanding shares of Common Stock of the Corporation.

 

    	Page 3 of 5

    	 

    

 

EXHIBIT
A

 

Section
5.06 Notwithstanding the limitations on conversion contained within Section 5.05 above, the limitations on conversion
contained therein may be waived, in the sole discretion of the Holder upon, and at the election of the Holder, not less than
sixty-one (61) days’ prior notice to the Corporation, and the provisions of the conversion limitation shall continue to
apply until such sixty-first (61st) day (or such later date, as determined by the Holder, as may be specified in
such notice of waiver).

 

Section
5.07 Effect of Subdivisions, Combinations and Dividends.

 

		(a)	In
                                         the event that the Corporation shall at any time subdivide the outstanding shares of
                                         Common Stock, or shall issue a stock dividend on the outstanding Common Stock, the Conversion
                                         Ratio in effect immediately prior to such subdivision or the issuance of such dividend
                                         shall be proportionately increased and shall continue to be proportionately increased
                                         through any subsequent subdivision, subdivisions, issuance or issuances.

 

		(b)	In
                                         the event that the Corporation shall at any time combine the outstanding shares of Common
                                         Stock, the Conversion Ratio in effect immediately prior to such combination shall be
                                         proportionately decreased and shall continue to be proportionately decreased through
                                         any subsequent combination or combinations.

 

Section
5.08 In no event may the Corporation combine or divide the number of shares of Series D Stock outstanding, nor change the
authorized number of shares of Series D Stock, except as otherwise approved by the affirmative vote or written consent of the
Holders of at least a sixty-seven percent (67%) of the Series D Stock issued and outstanding at the time of any such vote or
written consent.

 

Section
5.09 As used herein, the term “Face Value” shall mean Forty United States Dollars (US$40.00) per share of
Series D Stock. Notwithstanding the foregoing, if any agreement under which Series D Stock is subscribed specifies a
different Face Value, the Face Value so specified shall supersede and replace the Face Value specified herein.

 

ARTICLE
VI. Voting Rights of Series D Stockholders.

 

Section
6.01 Holders are entitled to vote on matters relating to modifications, adjustments, waivers or other changes or matters
relating only to Series D Stock. Each Holder shall have one (1) vote per each share on matters relating only to Series D
Stock.

 

Section
6.02 Definitions. For the purposes of this Article VI, the following terms shall have the meaning set forth
herein.

 

		(a)	An
                                         “Original Holder” shall mean any person that obtains any Series D Stock in
                                         any manner, directly from the Corporation, whether by purchase, gift, grant, the order
                                         of any court, state or federal agency, any arbitrator or in any other manner in any transaction.

 

		(b)	A
                                         “Subsequent Holder” shall mean any Holder that obtains any Series D Stock
                                         from any Original Holder in any transaction or series of transactions whereby the Subsequent
                                         holder is not in privity of contract with the Corporation as regards the transfer of
                                         any Series D Stock from an Original Holder.

 

		(c)	A
                                         “Shareholder Meeting” shall mean any annual, regular or special meeting of
                                         the shareholders, or any written consent held in lieu of any annual, regular or special
                                         meeting of the shareholders where any matters are presented to the Common stockholders
                                         of the Corporation for their vote, action or consideration.

 

		(d)	“IBCA”
                                         is the Illinois Business Corporation Act of 1983.

 

		(e)	An
                                         “Affirmative Vote” shall mean any vote of the shareholders at any Shareholder
                                         Meeting, that meets any and all requirements of the IBCA, the Articles of Incorporation
                                         and/or the By-Laws of the Corporation as they may relate to Shareholder Meetings, notices
                                         of Shareholder Meetings, voter thresholds required at any Shareholder Meetings and waiver
                                         of any notices of Shareholder Meetings.

 

Section
6.03 Voting Rights of Original Holders and Subsequent Holders related to matters presented to the Common
stockholders.

 

    	Page 4 of 5

    	 

    

 

EXHIBIT
A

 

		(a)	No Original Holder shall be
entitled to any vote at any Shareholder Meeting.

 

		(b)	Each
                                         Subsequent Holder shall be entitled to vote at any Shareholder Meeting and each such
                                         Subsequent Holder shall have one thousand (1,000) votes for each Series D share outstanding
                                         in their name on the books of the Corporation.

 

Section
6.04 Notwithstanding the above, no Subsequent Holder shall be entitled to vote at any Shareholder Meeting unless and until;

 

		(a)	the
                                         Corporation has either, fully complied with all of the requirements of Rule 14C (17 CFR
                                         § 240.14c-1 through 17 CFR § 240.14c-101, inclusive) as promulgated by the
                                         Securities and Exchange Commission (“SEC”) regarding notification of an Affirmative
                                         Vote by the written consent, specifically authorizing the Board of Directors to designate
                                         classes or series of preferred stock with voting and/or super majority voting rights;
                                         or

 

		(b)	the
                                         Corporation has fully complied with all of the requirements of Regulation 14A (17 CFR
                                         § 240.14a-1 through 17 CFR § 240.14b-2, inclusive) as promulgated by the SEC
                                         regarding the solicitation of proxies from shareholders and the Corporation has obtained
                                         the Affirmative Vote, specifically authorizing the Board of Directors to designate classes
                                         or series of preferred stock with voting and/or super majority voting rights; and

 

		(c)	the
                                         Corporation has filed an amendment to its Articles of Incorporation, authorizing the
                                         Board of Directors to designate classes or series of preferred stock with voting and/or
                                         super majority voting rights, subsequent to an Affirmative Vote and after the Corporation
                                         has fully complied with all of the requirements of either subsection (a) or (b) of this
                                         Section 6.04.

 

ARTICLE
VII. Certain Covenants.

 

Section
7.01 Any Holder of Series D Stock may proceed to protect and enforce its rights and the rights of such Holders by any
available remedy by proceeding at law or in equity, whether for the specific enforcement of any provision in this Certificate
of Designation or in aid of the exercise of any power granted herein, or to enforce any other proper remedy.

 

ARTICLE
VIII. Dividends.

 

Section
8.01 The Series D Stock shall not be entitled to dividends.

 

ARTICLE
IX. Notice to the Corporation.

 

Section
9.01 All notices and other communications required or permitted to be given to the Corporation hereunder shall be made by
first-class mail, postage prepaid, to the Corporation at its principal executive offices as may be fixed from time to time by
the Board of Directors. Any notice to a Holder shall me made to their address as set forth on the books and records of the
Corporation.

 

	 	PAWS
    PET COMPANY, INC.
	 	 	 
	 	By:	/s/
    Daniel Wiesel
	 	 	Daniel Wiesel,
    Chairman & CEO
	 	 	 
	Dated:
    December 27, 2013	 	 

 

    	Page 5 of 5EXHIBIT 10.3

 

EXHIBIT
B

 

ROYALTY
AGREEMENT

 

This
ROYALTY AGREEMENT (this “Royalty Agreement”), is made effective as of this 30th day of December 2013 (the “Effective
Date”), by and among MESA PHARMACY, INC., a California corporation (“MESA”) and PHARMACY DEVELOPMENT
CORP., a California corporation (“PDC”), both having as their principal place of business, 18013 Sky Park Circle,
Suite D, Irvine, CA 92614 (collectively referred to hereinafter as the “Parties”).

 

RECITALS

 

WHEREAS,
MESA is and has been a wholly owned subsidiary of PDC; and

 

WHEREAS,
PDC has entered into a Securities Exchange Agreement (the “SEA”) with THE PAWS PET COMPANY, INC. (“PAWS”),
whereby all of the ownership interests of MESA will be sold to PAWS; and

 

AGREEMENT

 

NOW,
THEREFORE, in consideration of the mutual covenants contained in this Royalty Agreement, and for other good and valuable consideration
including the cancellation of all outstanding intercompany loans due PDC by MESA, if any, the receipt and adequacy are hereby
acknowledged, the Parties agree as follows:

 

ARTICLE
I

DEFINITIONS

 

1.1
Definitions. Definitions of capitalized terms used in this Royalty Agreement shall have the meanings given in Appendix
A or elsewhere in the Royalty Agreement.

 

ARTICLE
II

ROYALTY
PAYMENTS

 

2.1
Royalties. MESA shall pay PDC five percent (5%) (the “Royalty”) of the amount actually collected by MESA as royalties
on each Prescription billed by Mesa during the Royalty Term, due and payable at the time each Prescription is collected. Uncollectable
Prescriptions will not be paid any royalty.

 

2.2
Termination of Royalty Obligations. This royalty payment obligation shall not terminate unless agreed to in writing by PDC
or the expiration of the Royalty Term as that term is defined herein below.

 

ARTICLE
III

REPORTS
AND PAYMENTS

 

3.1
Recordkeeping. MESA shall, and shall obligate its Affiliates to, keep full and accurate records (prepared in accordance with
United States Generally Accepted Accounting Principles consistently applied) of MESA’s or its Affiliates’ sales of
Prescriptions and such other matters as may affect the determination of any amount payable to PDC hereunder, in sufficient detail
to reasonably enable PDC or PDC’s representatives to determine any amounts payable to PDC under this Royalty Agreement.
Such records shall be kept at MESA’s or its Affiliates’ principal place of business and, with all necessary supporting
data, books and ledgers, shall, during all reasonable times for the 2 years following the end of the Accounting Period to which
each shall pertain, be open for inspection at reasonable times during normal business hours (and upon at least 30 days prior written
notice) no more than one time per calendar year by an independent audit firm selected by PDC (reasonably acceptable to MESA) for
the purpose of verifying the accuracy of any payment report required under this Royalty Agreement or any amount payable hereunder.
The results of each inspection shall be binding on both PDC and MESA absent mathematical error. PDC shall bear all costs associated
with such inspections.

 

    	Page 1 of 5

    	 

    

 

EXHIBIT
B

 

3.2
Reports. Within thirty (30) days after the end of each Accounting Period, MESA shall deliver to PDC a true and accurate report,
giving such particulars of the business conducted by MESA or its Affiliates during the preceding four (4) Accounting Periods under
this Royalty Agreement as are reasonably pertinent to an accounting for any royalty or other payments hereunder, along with the
amount of royalties payable for such Accounting Period. If no payments are due, it shall be so reported.

 

3.3
Accounting. With each quarterly payment, MESA shall deliver to PDC the report described in Section 3.2, which shall include,
but not be limited to, the following information:

 

	(a)		Quantity of each Prescription
sold by MESA or its Affiliates during the applicable Accounting Period;

 

	(b)		The monetary amount, in the
national currency of such country, of such sales;

 

	(c)		Actual gross sales and Net
Sales for each Prescription (by country);

 

	(d)		The currency conversion rate
used and U.S. dollar-equivalent of such sales; and

 

	(e)		Total royalties payable to
PDC including a calculation thereof. All reports under this Section 3.3 shall be confidential information of MESA

 

ARTICLE
IV

TERMINATION

 

4.1
Generally. This Royalty Agreement shall become effective on the Effective Date and shall expire on the expiration of the Royalty
Term.

 

4.2
Post-Expiration Obligations. Upon the expiration of this Royalty Agreement, MESA shall submit all reports required by Section
3 and pay PDC all royalties due or accrued on the sale of Prescriptions up to and including the date of expiration.

 

4.3
Survival. Upon the expiration of this Royalty Agreement, nothing herein shall be construed to release either party from any
obligation that matured prior to the date of such expiration and Section 5 shall survive any such expiration.

 

ARTICLE
V 

INDEMNIFICATION

 

5.1
Survival. All of the provisions of this Royalty Agreement shall survive the Closing indefinitely, except that the representations
and warranties of PDC, on the one hand, and the representations and warranties of MESA on the other hand, shall survive until
the first anniversary of the Closing Date.

 

5.2
Indemnity by PDC. PDC shall indemnify and hold MESA and MESA’s directors, officers and employees harmless against and
in respect of any and all damages, losses, claims, penalties, liabilities, costs and expenses (including, without limitation,
all fines, interest, reasonable and actual legal fees and expenses and amounts paid in settlement), that arise from or relate
or are attributable to (and without giving effect to any tax benefit to the indemnified party) (a) any misrepresentation or breach
of any warranty by PDC in the Royalty Agreement or (b) any breach of any covenant or Royalty Agreement on the part of PDC pursuant
to its obligations under the Royalty Agreement.

 

5.3
Indemnity by MESA. MESA shall indemnify and hold PDC and PDC’s directors, officers and employees harmless against and
in respect of any and all damages, losses, claims, penalties, liabilities, costs and expenses (including, without limitation,
all fines, interest, reasonable and actual legal fees and expenses and amounts paid in settlement), that arise from or relate
or are attributable to (and without giving effect to any tax benefit to the indemnified party) (a) any misrepresentation or breach
of any warranty by MESA in the Agreements or (b) any breach of any covenant or agreement on the part of MESA pursuant to its obligations
under the Royalty Agreement.

 

    	Page 2 of 5

    	 

    

 

EXHIBIT
B

 

5.4
Notice to Indemnitor; Right of Parties to Defend. Promptly after the assertion of any claim by a third party or occurrence
of any event which may give rise to a claim for indemnification from an indemnifying party (“Indemnitor”) under this
Article IV, an indemnified party (“Indemnitee”) shall notify the Indemnitor in writing of such claim. The Indemnitor
shall have the right to assume the control and defense of any such action (including, but without limitation, tax audits), provided
that the Indemnitee may participate in the defense of such action subject to the Indemnitor’s reasonable direction and at
Indemnitee’s sole cost and expense. The party contesting any such claim shall be furnished all reasonable assistance in
connection therewith by the other party and be given full access to all information relevant thereto. In no event shall any such
claim be settled without the Indemnitor’s consent.

 

ARTICLE
VI

MISCELLANEOUS

 

6.1
Fees and Expenses. Each party to this Royalty Agreement shall pay the fees and expenses of its or its advisers, counsel, accountants
and other experts, if any, and all other expenses incurred by such party incident to the negotiations, preparation, execution,
delivery and performance of this Royalty Agreement.

 

6.2
Entire Agreement; Amendments. This Royalty Agreement, together with the exhibits and schedules hereto, contains the entire
understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and
schedules.

 

6.3
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be
in writing and shall be delivered (a) by hand; (b) by recognized overnight courier; or (c) by certified mail, return receipt requested,
postage-prepaid. All of the foregoing shall be deemed given and effective on (x) receipt, if delivered by hand; (y) the next business
day after deposit, if sent by nationally recognized overnight courier; or (c) the third (3rd) business day after deposit, if mailed.
The address for such notices and communications shall be as follows:

 

	If to MESA:	18013 Sky Park Circle,
    Suite D
	 	Irvine, California 92614
	 	Attn: CEO
	 	 
	If to PDC:	18013 Sky Park Circle, Suite
    D
	 	Irvine, California 92614
	 	Attn: COO

 

or
such other address as maybe designated by party in writing hereafter, by notice (given in the same manner).

 

6.4
Amendments; Waivers. No provision of this Royalty Agreement may be waived or amended except in a written instrument signed,
in the case of an amendment, by all the parties; or, in the case of a waiver, by the party against whom enforcement of any such
waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Royalty Agreement shall
be deemed to be a continuing waiver in the future or a waiver of any other provision, condition or requirement hereof, nor shall
any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right accruing
to it thereafter.

 

6.5
Headings. The headings herein are for convenience only, do not constitute a part of this Royalty Agreement and shall not be
deemed to limit or affect ay of the provisions hereof.

 

6.6
Successors and Assigns. This Royalty Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns. Neither party may assign this Royalty Agreement or any of the rights or obligations hereunder without the
written consent of the other party, which consent shall not unreasonably be withheld.

 

    	Page 3 of 5

    	 

    

 

EXHIBIT
B

 

6.7
No Third-Party Beneficiaries. This Royalty Agreement is intended for the benefit of the parties hereto and their respective
successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

6.8
Governing Law. This Royalty Agreement shall be governed by and construed and enforced in accordance with the internal laws
of California without regard to the principles of conflicts of law thereof. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in Washoe County, Nevada, for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the interpretation
or enforcement of this Agreement), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any manner permitted by law.

 

6.9
Attorneys’ Fees. In any suit, action or proceeding brought with respect to interpretation or enforcement of this Agreement,
the prevailing party shall be entitled to recover attorneys’ fees and costs from the non-prevailing party at both the trial
and appellate levels.

 

6.10
Construction. In the construction of this Royalty Agreement, the rule of construction that a document is to be construed most
strictly against a party who prepared the same shall not be applied, it being agreed that all parties have participated in the
preparation of the final form of this Royalty Agreement.

 

6.11
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other
party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered
by facsimile or .pdf transmission, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) the same with the same force and effect as if such facsimile signature page were an original
thereof.

 

6.12
Severability. In case any one or more of the provisions of this Agreement shall be invalid or unenforceable in any respect,
the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affecting or impaired
thereby and the parties will attempt to agree upon a valid and enforceable provision that shall be a reasonable substitute therefore,
and upon so agreeing, shall incorporate such substitute provision in this Agreement.

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

 

	 	MESA
PHARMACY, INC.
	 	 	 
	 	By:	/s/
                                         Andrew Do
	 	Name:	Andrew
                                         Do
	 	Title:	Chief
                                         Executive Officer
	 	 	 
	 	PHARMACY
DEVELOPMENT CORP.
	 	 	 
	 	By:	/s/
                                         Edward Kurtz
	 	Name:	Edward
                                         Kurtz
	 	Title:	Chief
     Operating Officer

 

    	Page 4 of 5

    	 

    

 

EXHIBIT
B

 

APPENDIX
A

DEFINITIONS

 

	Accounting
    Period	 	The
    end of each month commencing on the date that is the end of the first month after the Effective Date of this Royalty Agreement.
	 	 	 
	Affiliate	 	(a)	in
    the case of corporate entities, direct or indirect ownership of at least 50% of the stock or participating shares entitled
    to vote for the election of directors or the power to control such entity; and
	 	 	 	 
	 	 	(b)	in
    the case of non-corporate entities, direct or indirect ownership of at least 50% of the equity interest or the power to control
    such entity.
	 	 	 	 
	Net
    Sales	 	Without
    duplication, all Prescription-based gross revenues invoiced by MESA or any of its Affiliates of Prescriptions in the jurisdiction
    in which such sales occurs, to the extent attributable, less all reasonably related expenses or other accruals relating thereto
    including but not limited to:
	 	 	 	 
	 	 	(1)	the
    cost to MESA of manufacturing and distribution of Prescriptions;
	 	 	 	 
	 	 	(2)	royalties
    or the like paid to third parties on Prescriptions;
	 	 	 	 
	 	 	(3)	discounts,
    rebates and deductions, or any other consideration accrued to customers (including group purchasing organizations) based on
    volumes and/or revenues commercialized, or any other deductions or the like allowed (whether in cash or trade) to wholesalers
    or distributors or to other customers for quantity purchases, prompt payments or other special conditions;
	 	 	 	 
	 	 	(4)	credits,
    write-offs, collection fees, allowances or refunds, not exceeding the original invoice amount, for claims, returns, collections
    or bad debts, and any other allowances made for returned or deficient goods or services;
	 	 	 	 
	 	 	(5)	financing
fees and expenses as a result of the sale or hypothecation of any Prescriptions.

	 	 	 	 
	 	 	(6)	transportation
expenses, including any and all carriage or insurance charges, packaging, freight, and costs of delivery; and

	 	 	 	 
	 	 	(7)	sales
and use taxes and other fees or taxes imposed by any government or governmental agency, including, but not limited to any import,
export or customs duties.

	 	 	 	 
	 	 	Net
    Sales shall be determined from books and records maintained in accordance with United States Generally Accepted Accounting
    Principles, consistently applied throughout the organization and across all sales of Prescription are giving rise to Net Sales.
	 	 	 	 
	Prescription(s)	 	Any
    compounded pain management cream produced by MESA under this Royalty Agreement,
	 	 	 	 
	Royalty
    Term	 	The
    date that is twenty (20) years from the Effective Date.
	 	 	 	 
	Territory	 	The
    entire world.

 

    	Page 1 of 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]